Dr. Berenson on a Study of Pomalidomide in R/R Myeloma

James R. Berenson, MD
Published: Friday, Dec 13, 2013

James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 American Society of Hematology (ASH) Meeting.

This is the first study using pomalidomide with doxil or pegylated liposomal doxorubicin, Berenson says. In the study, patients who progressed through lenalidomide responded to the combination. This combination was also well tolerated and looks promising going forward.

This phase I/II study is leading to other studies aimed to answer the question as to whether or not lenalidomide can be replaced with pomalidomide to elicit responses in patients failing combination therapy. Berenson says that based on this study, he hypothesizes that patients will respond in future analyses.

SELECTED
LANGUAGE
James R. Berenson, MD, Medical and Scientific Director, Institute for Myeloma & Bone Cancer Research, discusses a phase I/II study looking at pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed/refractory multiple myeloma. The study was presented at the 2013 American Society of Hematology (ASH) Meeting.

This is the first study using pomalidomide with doxil or pegylated liposomal doxorubicin, Berenson says. In the study, patients who progressed through lenalidomide responded to the combination. This combination was also well tolerated and looks promising going forward.

This phase I/II study is leading to other studies aimed to answer the question as to whether or not lenalidomide can be replaced with pomalidomide to elicit responses in patients failing combination therapy. Berenson says that based on this study, he hypothesizes that patients will respond in future analyses.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x